GlassScriptPhysician profile
Joseph R Steeger
NPI 1255386595
$3,248.14
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $827 · 2021: $975.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,054.11 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $484.17 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $435.25 | 2019-2021 | |
| Philips North America LLC | $172.86 | 2019-2021 | |
| Genentech USA, INC. | $155.08 | 2019-2020 | |
| Genzyme Corporation | $152.01 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $121.33 | 2019-2020 | |
| Mylan Specialty L.P. | $68.52 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.12 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $64.13 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $55.09 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $52.93 | 2019 | |
| Pfizer INC. | $41.24 | 2019 | |
| Grifols USA, LLC | $39.92 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $36.01 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $27.52 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $25.75 | 2019-2020 | |
| Optinose US, INC. | $25.36 | 2019 | |
| Harmony Biosciences LLC | $17.78 | 2020 | |
| Shire North American Group INC | $14.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.66 | 2019 | |
| Merck Sharp & Dohme LLC | $14.32 | 2021 | |
| Mallinckrodt Hospital Products INC. | $14.24 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.21 | 2019 | |
| Circassia INC. | $13.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.94 | 2021 | |
| Electromed, INC. | $12.91 | 2021 | |
| Insmed, INC. | $11.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Steeger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.